[White Paper] Accelerating Immune Checkpoint Drug Discovery through Functional Cell-Based Assays

[White Paper] Accelerating Immune Checkpoint Drug Discovery through Functional Cell-Based Assays
Version:
20218

Year:
2021

Immune checkpoint receptors play a key role in maintaining antitumor immunity, avert immunopathology, and modulate overall immune homeostasis. However, cancer cells have adopted clever ways to hijack the modulation of these receptors, thus evading immune surveillance and successfully proliferating. To counter this takeover, targeted immune-modulators, such as monoclonal antibodies directed against checkpoint modulators, present a promising approach to cancer therapy, often referred to as immunotherapy. These antibodies have the ability to selectively block or stimulate specific checkpoint receptors and activate immune effector cells. In the past decade, various clinical studies have shown that such immune checkpoint modulators check tumor growth and result in stable clinical responses. Today, there are thousands of immunotherapy drug candidates in various stages of development.
From discovery to market release, these drug candidates require mechanism-of-action (MOA) based functional cell-based assays as characterization tools that can attest to their desired therapeutic activity in combating cancer. However, developing such cell-based assays has proved to be quite challenging. They are often difficult to establish in quality control (QC) labs, and typically have long and complicated assay protocols or use primary human cells. In this paper, we focus on accelerating the pace of immunotherapy drug discovery through Eurofins DiscoverX’s off-the-shelf, MOA-based functional cell-based assays designed to support the drug discovery process up to late-stage development and post-market surveillance.